Shares of Evotec SE (NASDAQ:EVO - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $4.21, but opened at $3.85. Evotec shares last traded at $3.83, with a volume of 112,446 shares traded.
Evotec Stock Performance
The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The business's fifty day moving average is $4.30 and its 200 day moving average is $4.09.
Institutional Trading of Evotec
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock worth $9,616,000 after purchasing an additional 602,858 shares in the last quarter. DCF Advisers LLC raised its holdings in shares of Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after purchasing an additional 12,816 shares in the last quarter. Lighthouse Investment Partners LLC bought a new stake in shares of Evotec in the 4th quarter worth approximately $166,000. Bank of America Corp DE raised its holdings in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after purchasing an additional 9,289 shares in the last quarter. Finally, CSS LLC IL bought a new stake in shares of Evotec in the 4th quarter worth approximately $50,000. 5.81% of the stock is currently owned by institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
